ARWR
Price
$15.66
Change
-$0.30 (-1.88%)
Updated
Jun 25 closing price
Capitalization
2.16B
46 days until earnings call
RGNX
Price
$8.54
Change
-$0.02 (-0.23%)
Updated
Jun 25 closing price
Capitalization
430.32M
34 days until earnings call
Interact to see
Advertisement

ARWR vs RGNX

Header iconARWR vs RGNX Comparison
Open Charts ARWR vs RGNXBanner chart's image
Arrowhead Pharmaceuticals
Price$15.66
Change-$0.30 (-1.88%)
Volume$942.76K
Capitalization2.16B
REGENXBIO
Price$8.54
Change-$0.02 (-0.23%)
Volume$651.97K
Capitalization430.32M
ARWR vs RGNX Comparison Chart in %
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. RGNX commentary
Jun 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Buy and RGNX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 26, 2025
Stock price -- (ARWR: $15.66 vs. RGNX: $8.54)
Brand notoriety: ARWR: Notable vs. RGNX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 56% vs. RGNX: 54%
Market capitalization -- ARWR: $2.16B vs. RGNX: $430.32M
ARWR [@Biotechnology] is valued at $2.16B. RGNX’s [@Biotechnology] market capitalization is $430.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $312.97B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARWR and RGNX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 3 TA indicator(s) are bullish while RGNX’s TA Score has 4 bullish TA indicator(s).

  • ARWR’s TA Score: 3 bullish, 4 bearish.
  • RGNX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, RGNX is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а +0.26% price change this week, while RGNX (@Biotechnology) price change was -0.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.95%. For the same industry, the average monthly price growth was +31.79%, and the average quarterly price growth was +15.79%.

Reported Earning Dates

ARWR is expected to report earnings on Aug 11, 2025.

RGNX is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+1.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($2.16B) has a higher market cap than RGNX($430M). RGNX YTD gains are higher at: 10.479 vs. ARWR (-16.702). ARWR has higher annual earnings (EBITDA): -68.12M vs. RGNX (-122.44M). ARWR has more cash in the bank: 1.1B vs. RGNX (268M). RGNX has less debt than ARWR: RGNX (79.8M) vs ARWR (388M). ARWR has higher revenues than RGNX: ARWR (545M) vs RGNX (157M).
ARWRRGNXARWR / RGNX
Capitalization2.16B430M503%
EBITDA-68.12M-122.44M56%
Gain YTD-16.70210.479-159%
P/E RatioN/AN/A-
Revenue545M157M347%
Total Cash1.1B268M409%
Total Debt388M79.8M486%
FUNDAMENTALS RATINGS
ARWR vs RGNX: Fundamental Ratings
ARWR
RGNX
OUTLOOK RATING
1..100
6254
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
5962
P/E GROWTH RATING
1..100
221
SEASONALITY SCORE
1..100
8585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGNX's Valuation (73) in the Biotechnology industry is in the same range as ARWR (94). This means that RGNX’s stock grew similarly to ARWR’s over the last 12 months.

RGNX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that RGNX’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's SMR Rating (96) in the Biotechnology industry is in the same range as RGNX (97). This means that ARWR’s stock grew similarly to RGNX’s over the last 12 months.

ARWR's Price Growth Rating (59) in the Biotechnology industry is in the same range as RGNX (62). This means that ARWR’s stock grew similarly to RGNX’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is in the same range as RGNX (21). This means that ARWR’s stock grew similarly to RGNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRRGNX
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 16 days ago
75%
Declines
ODDS (%)
Bearish Trend 10 days ago
83%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ERBIX19.07N/A
N/A
Eaton Vance RBA Equity Strategy Fd Cl I
JNBCX10.09N/A
N/A
JPMorgan Income Builder C
AXVIX17.28N/A
N/A
Acclivity Small Cap Value I
FAVAX23.99N/A
N/A
Fidelity Advisor Equity Value A
OILVX19.37-0.10
-0.51%
Optimum Large Cap Value Instl

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-1.88%
DNLI - ARWR
54%
Loosely correlated
+0.35%
IMNM - ARWR
53%
Loosely correlated
-2.69%
YMAB - ARWR
53%
Loosely correlated
-4.29%
RGNX - ARWR
53%
Loosely correlated
-0.23%
BEAM - ARWR
52%
Loosely correlated
-2.27%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with DNLI. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-0.23%
DNLI - RGNX
55%
Loosely correlated
+0.35%
ARWR - RGNX
53%
Loosely correlated
-1.88%
BEAM - RGNX
53%
Loosely correlated
-2.27%
VYGR - RGNX
51%
Loosely correlated
-2.00%
XNCR - RGNX
50%
Loosely correlated
+3.51%
More